Evolving '-omics' technologies in the drug development process

Expert Opinion on Drug Discovery

Volumn 2, Issue 4, 2007, Pages 431-436

  Pavelic, Sandra Kraljevic ^a   Saban, Nina ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

Biologic pathway; Mass spectrometry; Microarrays; Protein array; Systems biology

Indexed keywords

AROMATASE; BRCA1 PROTEIN; BRCA2 PROTEIN; CERIVASTATIN; ROFECOXIB; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

ACCURACY; ARTICLE; DNA MICROARRAY; DRUG APPROVAL; DRUG EFFICACY; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; ECONOMIC ASPECT; FUNCTIONAL GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; MATHEMATICAL MODEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REPRODUCIBILITY; SENSITIVITY ANALYSIS; SERIAL ANALYSIS OF GENE EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; STANDARDIZATION;

EID: 34447503276     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2.4.431     Document Type: Article

References (28)

1. FISHMAN MC, PORTER JA: Pharmaceuticals - a new grammar for drug discovery. Nature (2005) 437(7058):491-493.
2. GREENER M: Drug safety on trial - last year's withdrawal of the anti-arthritis drug Vioxx triggered a debate about how to better monitor drug safety even after approval. EMBO Rep. (2005) 6(3):202-204.
3. DIMASI JA, HANSEN RW, GRABOWSKI HG: The price of innovation: new estimates of drug development costs. J. Health Econ. (2003) 22(2):151-185.
4. KRALJEVIC S, STAMBROOK PJ, PAVELIC K: Accelerating drug discovery - although the evolution of '-omics' methodologies is still in its infancy, both the pharmaceutical industry and patients could benefit from their implementation in the drug development process. EMBO Rep. (2004) 5(9):837-842.
5. HOOD L: Systems biology: integrating technology, biology and computation. Mech. Ageing Devel. (2003) 124(1):9-16.
6. CHO CR, LABOW M, REINHARDT M, VAN OOSTRUM J, PEITSCH MC: The application of systems biology to drug discovery. Curr. Opin. Chem. Biol. (2006) 10(4):294-302.
7. AUFFRAY C, IMBEAUD S, ROUX-ROUQUIE M, HOOD L: From functional genomics to systems biology: concepts and practices. C. R. Biol. (2003) 326(10-11):879-892.
8. BUTTE A: The use and analysis of microarray data. Nat. Rev. Drug Discov. (2002) 1(12):951-960.
9. MILLS JC, ROTH KA, CAGAN RL, GORDON JI: DNA microarrays and beyond: completing the journey from tissue to cell. Nat. Cell Biol. (2001) 3(8):E175-E178.
10. HUGHES TR, MAO M, JONES AR et al.: Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nat. Biotechnol. (2001) 19(4):342-347.
11. ENGLE LJ, SIMPSON CL, LANDERS JE: Using high-throughput SNP technologies to study cancer. Oncogene (2006) 25(11):1594-1601.
12. LYNCH TJ, BELL DW, SORDELLA R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med (2004) 350(21):2129-2139.
13. OSLIN DW, BERRETTINI W, KRANZLER HR et al.: A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology (2003) 28(8):1546-1552.
14. BUCK MJ, LIEB JD: ChIP-chip: considerations for the design, analysis, and application of genome-wide chromatin immunoprecipitation experiments. Genomics (2004) 83(3):349-360.
15. KOLKER E, HIGDON R, HOGAN JM: Protein identification and expression analysis using mass spectrometry. Trends Microbiol. (2006) 14(5):229-235.
16. KILALJEVIC S, SEDIC M, SCOTT M et al.: Casting light on molecular events underlying anti-cancer drug treatment: what can be seen from the proteomics point of view? Cancer Treat. Rev. (2006) 32(8):619-629.
17. SHAW MM, RIEDERER BM: Sample preparation for two-dimensional gel electrophoresis. Proteomics (2003) 3(8):1408-1417.
18. MANN M, HENDRICKSON RC, PANDEY A: Analysis of proteins and proteomes by mass spectrometry. Ann. Rev. Biochem. (2001) 70:437-473.
19. ROE MR, GRIFFIN TJ: Gel-free mass spectrometry-based high throughput proteomics: tools for studying biologic response of proteins and proteomes. Proteomics (2006) 6(17):4678-4687.
20. VOLMER DA, SLENO L: Modern drug discovery and the progression toward a universal mass spectrometer. Anal. Bioanal. Chem. (2005) 381(1):90-92.
21. ADKINS JN, MONROE ME, AUBERRY KJ et al.: A proteomic study of the HUPO Plasma Proteome Project's pilot samples using an accurate mass and time tag strategy. Proteomics (2005) 5(13):3454-3466.
22. AN HJ, MIYAMOTO S, LANCASTER KS et al.: Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer. J. Proteome Res. (2006) 5(7):1626-1635.
23. ANDRE M, LE CAER JP, GRECO C et al.: Proteomic analysis of the tetraspanin web using LC-ESI-MS/MS and MALDI-FTICR-MS. Proteomics (2006) 6(5):1437-1449.
24. BERGEN HR III, VASMATZIS G, CLIBY WA et al.: Discovery of ovarian cancer biomarkers in serum using NanoLC electrospray ionization TOF and FT-ICR mass spectrometry. Dis. Markers (2003) 19(4-5):239-249.
25. AEBERSOLD R: Constellations in a cellular universe. Nature (2003) 422(6928):115-116.
26. PAN S, ZHANG H, RUSH J et al.: High throughput proteome screening for biomarker detection. Mol. Cell. Proteomics (2005) 4(2):182-190.
27. UTTAMCHANDANI M, WANG J, YAO SQ: Protein and small molecule microarrays: powerful tools for high-throughput proteomics. Mol. Biosyst. (2006) 2(1):58-68.
28. BRAZMA A, KRESTYANINOVA M, SARKANS U: Standards for systems biology. Nat. Rev. Genet. (2006) 7(8):593-605.